Get notified when BCTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsBriaCell files routine Q2 2026 financials via Canadian subsidiary disclosure
Filed March 31, 2026 · Period ending March 31, 2026 · ~1 min read
Key Changes
-
low
BriaPro Therapeutics, BriaCell's subsidiary, filed unaudited financial statements and management discussion for the three and six months ended January 31, 2026 with British Columbia and Alberta securities regulators.
Item 8.01 view on EDGAR → -
low
Filing made under Regulation FD to ensure U.S. investors have access to the same quarterly financial information disclosed in Canada.
8-K: Reg FD Disclosure view on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (RBLX 10-Q) is open in full — no account needed.
Partner
Trade BCTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 10, 2026 · How we verify